Evidence map›Paper›PMID 37388778›Full record

ArticleWorld journal of clinical cases2023

Elabela is a reliable biomarker for predicting early onset preeclampsia: A comparative study.

Eham Amer Ali, Wassan Nori, Alea Farhan Salman, Taghreed S Saeed Al-Rawi, Ban H Hameed, Raid M Al-Ani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eham Amer AliDepartment of Chemistry and Biochemistry, Mustansiriyah University, Baghdad 10052, Iraq.
Wassan NoriDepartment of Obstetrics and Gynecology, Mustansiriyah University, Baghdad 10052, Iraq.
Alea Farhan SalmanNational Central of Hematology, Mustansiriyah University, Baghdad 10052, Iraq.
Taghreed S Saeed Al-RawiDepartment of Biochemistry, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq.
Ban H HameedDepartment of Obstetrics and Gynecology, Mustansiriyah University, Baghdad 10052, Iraq.
Raid M Al-AniDepartment of Surgery/Otolaryngology, University of Anbar College of Medicine, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq. med.raed.alani2003@uoanbar.edu.iq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreeclampsia (PE) is a multisystemic metabolic disease with an undetermined etiology. PE is a worldwide cause of maternal and perinatal morbidity, subdivided into early (EoPE) and late-onset (LoPE) according to 34 wk of gestation as a divider. Many researchers investigated biomarkers for predicting PE to halt its consequences on the feto-maternal outcome. Elabela (Ela) is a newly discovered peptide hormone that was implicated in PE pathogenesis. Earlier rodent studies discussed Ela's role in controlling blood pressure. Moreover, Ela deficiency was associated with PE development.

aimTo test whether plasma Ela could serve as a reliable marker for predicting PE based on the time of onset (EoPE

methodsThis case-control study recruited (

resultsSerum Ela was significantly reduced in EoPE compared to LoPE and healthy controls (

conclusionA strong correlation of serum Ela with PE parameters with excellent sensitivity and specificity in distinguishing EoPE independent of the BMI, age, and blood pressure which makes Ela a recommendable marker in screening. Further research is warranted to explore prognostic and therapeutic applications for Ela in PE.

Indexed as

Early onset preeclampsiaElabelaLate-onset preeclampsiaPredictionPreeclampsiaPregnant women

Identifiers

PMID37388778
PMCPMC10303616

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.